SCHEMBL1864892

SCHEMBL1864892

O=C(O)CCCCC(=O)OC(C(=O)O)C(O)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.42
TSHR P16473 2/20 0.41
NFKB1 P19838 2/20 0.41
PMP22 Q01453 1/20 0.41
SLC22A6 Q4U2R8 1/20 0.37
MMP1 P03956 1/20 0.36
MMP2 P08253 1/20 0.36
MMP3 P08254 1/20 0.36
MMP9 P14780 1/20 0.36
MMP13 P45452 1/20 0.36
FFAR1 O14842 2/20 0.35
FFAR4 Q5NUL3 2/20 0.35
GPR84 Q9NQS5 1/20 0.35
AKR1B1 P15121 1/20 0.35
CYP2D6 P10635 1/20 0.35
FOLH1 Q04609 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35
SRC P12931 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3749621 0.96 TSHR (0.45) LMNATSHRNFKB1PMP22SLC22A6
SCHEMBL14935874 0.94 LMNA (0.39) LMNATSHRPMP22MMP1MMP2
SCHEMBL27860849 0.92 LMNA (0.42) LMNATSHRPMP22MMP1MMP2
SCHEMBL3749627 0.90 MMP1 (0.39) LMNATSHRSLC22A6MMP1MMP2
SCHEMBL94758 0.88 MMP1 (0.38) LMNATSHRMMP1MMP2MMP3
SCHEMBL17377946 0.87 LMNA (0.38) LMNATSHRNFKB1PMP22SLC22A6
Cadaverine Tartrate SCHEMBL6754064 0.86 TSHR (0.40) LMNATSHRMMP1MMP2MMP3
Malic Acid SCHEMBL27687431 0.86 SMN1; SMN2 (0.50) LMNATSHRPMP22MMP1MMP2
SCHEMBL1168152 0.86 MMP1 (0.42) TSHRMMP1MMP2MMP3MMP9
SCHEMBL20590957 0.85 LMNA (0.55) LMNATSHRPMP22ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6331206-B1 DI- OR TRICARBOXYLIC ACID IS BOTH CATALYST AND CROSSLINKING AGENT WITH A POLYSILOXANE TO FORM AN ESTER, COATING FOR A SHAVER; EXHIBITS INSENSITIVITY TO WATER SO THAT STORAGE AND HANDLING CAN TAKE PLACE IN AIR WITHOUT THE PROPERTIES OF THE U.S. PHILIPS CORPORATION 2001-12-18 US claimed
WO-2024074589-A1 PLANT-BASED CHEESE OF THE HALF-HARD TYPE Upfield Europe B.V. (NL) 2024-04-11 WO disclosed
WO-2023052977-A1 COMPOSITIONS, METHODS AND USES THEREOF AVACA PHARMA PRIVATE LIMITED (IN) 2023-04-06 WO disclosed
EP-4132506-A1 CARBOXYLATE LIGAND MODIFIED FERRIC IRON HYDROXIDE COMPOSITIONS FOR USE IN THE TREATMENT OR PREVENTION OF IRON DEFICIENCY ASSOCIATED WITH LIVER DISEASES Nemysis Limited (IE) 2023-02-15 EP disclosed
US-11206844-B2 Dry blend for making extended cheese product Allied Blending & Ingredients Inc. (US) 2021-12-28 US disclosed
US-20210337820-A1 DRY BLEND FOR MAKING ANALOGUE CHEESE Allied Blending LP 2021-11-04 US disclosed
WO-2021204705-A1 CARBOXYLATE LIGAND MODIFIED FERRIC IRON HYDROXIDE COMPOSITIONS FOR USE IN THE TREATMENT OR PREVENTION OF IRON DEFICIENCY ASSOCIATED WITH LIVER DISEASES NEMYSIS Ltd. (IE) 2021-10-14 WO disclosed
US-11089793-B2 Dry blend for making analogue cheese Allied Blending LP (US) 2021-08-17 US disclosed
CN-108064152-B Antibacterial compositions comprising copper oxo-hydroxide nanoparticles and their use as biocides 英国研究与创新署 2021-07-09 CN disclosed
EP-2925152-B1 IMPROVED DRY BLEND FOR MAKING CHEESE ANALOGUE ALLIED BLENDING & INGREDIENTS INC (US) 2021-01-13 EP disclosed
WO-2013138728-A1 IMPROVED DRY BLEND FOR MAKING ANALOGUE CHEESE ALLIED BLENDING & INGREDIENTS, INC (US) 2013-09-19 WO disclosed
US-20130243926-A1 DRY BLEND FOR MAKING ANALOGUE CHEESE ALLIED BLENDING & INGREDIENTS, INC. (US) 2013-09-19 US disclosed
US-20130122177-A1 DRY BLEND FOR MAKING EXTENDED CHEESE PRODUCT Allied Blending & Ingredients Inc. (US) 2013-05-16 US disclosed
WO-2013070874-A1 IMPROVED DRY BLEND FOR MAKING EXTENDED CHEESE PRODUCT ALLIED BLENDIND & INGREDIENTS INC. (US) 2013-05-16 WO disclosed
US-20110105443-A1 SALTS OF MEMANTINE AND COX-INHIBITORS AND THEIR CRYSTAL FORM IN THE TREATMENT OF PAIN LABORATORIES DEL DR. ESTEVE, S.A. (ES) 2011-05-05 US disclosed
EP-2206767-A2 Solid cleaning compositions Ecolab INC. (US) 2010-07-14 EP disclosed
EP-2098500-A1 Salts of menantine and cox-inhibitors and their crystal form in the treatment of pain Laboratorios Del. Dr. Esteve, S.A. (ES) 2009-09-09 EP disclosed
US-20040247758-A1 Food product H. J. HEINZ COMPANY 2004-12-09 US disclosed
CN-1085051-C Foaming coffee creamer and instant hot cappuccino KRAFT FOODS INC (US) 2002-05-22 CN disclosed
CN-1164340-A Foaming coffee creamer and instant hot cappuccino KRAFT FOODS INC (US) 1997-11-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105443-A1 SALTS OF MEMANTINE AND COX-INHIBITORS AND THEIR CRYSTAL FORM IN THE TREATMENT OF PAIN OPRK1, GRIN2A, HTR2A LMNA 1277/4885TSHR 4171/4885NFKB1 1953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.